

Major and minor histocompatibility antigens to NIMA

Prediction of a tolerogenic NIMA effect

Masahiro Hirayama¹ and Eiichi Azuma^{2,*}

¹Department of Pediatrics and ²Cell Transplantation; Mie University Graduate School of Medicine; Tsu, Mie Japan

Key words: NIMA, tolerance, major histocompatibility antigen, minor histocompatibility antigen, GVHD

Abbreviations: NIMA, non-inherited maternal antigens; MHC, major histocompatibility; MiHA, minor histocompatibility antigens; MMc, maternal microchimerism; GVHD, graft-versus-host disease; MLR, mixed lymphocyte reaction; ELISPOT, enzyme-linked immunospot

Submitted: 01/20/11

Accepted: 02/10/11

DOI: 10.4161/chim.2.1.15127

*Correspondence to: Eiichi Azuma;
Email: e-azuma@clin.medic.mie-u.ac.jp

Addendum to: Araki M, Hirayama M, Azuma E, Kumamoto T, Iwamoto S, Toyoda H, et al. Prediction of reactivity to noninherited maternal antigen in MHC-mismatched, minor histocompatibility antigen-matched stem cell transplantation in a mouse model. *J Immunol* 2010; 185:7739–45; PMID: 21078914; DOI: 10.4049/jimmunol.1001226

The immunologic effects of developmental exposure to non-inherited maternal antigens (NIMA) are heterogeneous, either tolerogenic or immunogenic. The role of minor histocompatibility antigens (MiHA) in NIMA effects is unknown. We have recently reported that the NIMA effect can be classified into two distinct reactivities, low and high responder, to NIMA in utero and during nursing depending on the degree of maternal microchimerism (MMc) and Foxp3 expression of peripheral blood CD4⁺CD25⁺ cells after graft-versus-host disease (GVHD) induction. These reactivities were predictable before transplantation, using an MLR-ELISPOT (mixed lymphocyte reaction; enzyme-linked immunospot) assay by comparing the number of IFN γ -producing cells stimulated with NIMA. Moreover, this assay was also applicable in both major and minor NIMA-mismatched setting. These observations are clinically relevant and suggest that it is possible to predict the immunological tolerance to NIMA.

There have been several investigations of NIMA.^{1,2} The immunologic effects of developmental exposure to NIMA are heterogeneous.³⁻⁵ The precise mechanisms of the heterogeneity are still under investigation. The relevance of MiHA in NIMA effect has not been reported. Not only in the MHC-identical but also in the MHC-haploidentical situation, MiHA alloreactivities may be induced upon transplantation.⁶ Therefore, focusing on the NIMA effect to H-2 is clinically relevant. In addition, it remains to be studied whether or not

particular microchimeric cell types are associated with either a sensitized or a tolerated MiHA immunization status.

The mouse MiHA loci confer a wide range of immunogenicity ranging from weakly to strongly immunogenic.⁷⁻⁹ Recent studies have provided evidence that GVHD could be caused by a limited number of MiHA, including H4, H7, H13, H28, H60 and H-Y.¹⁰⁻¹² This MiHA immunodominance was manifested on genetically varied backgrounds among B10, BALB/c and DBA/2 strain.^{7,13,14} So far, there has been no report distinguishing H-2 from MiHA as NIMA. We have classified mouse models of NIMA based on major and minor histocompatibility antigens to NIMA (Table 1). In our current study, all B10 congenic mice were used as NIMA model, and those MiHA had matched entirely in this system (Table 1b). On the other hand, in the conventional model (Table 1a), the NIMA is not only H-2^d but also noninherited MiHA of DBA/2. Therefore, our NIMA mouse model, but not conventional NIMA model, did not affect immunogenicity of MiHA. We examined the tolerogenic potential of NIMA exposure for H-2 of class I and II disparities without any influences of the MiHA.¹⁵ Contrary to previous reports that showed an apparent NIMA effect,^{1,16} we have described no evidence of the NIMA effect. The reason for the difference remains to be determined, but it could be due to the abrogation of the MiHA effect in our system.

Next, we analyzed whether the differences in the effects of NIMA underlie the individual responses to alloantigen by MLR. MLR assay demonstrated that

Table 1. Major and minor histocompatibility antigens to NIMA

Mating combination	Offspring	NIMA ^{H-2}	NIMA ^{MiHA}
(a) B6 male x B6D2F1 female (conventional model: major + minor)	H-2 ^{b/b}	H-2 ^d	Noninherited MiHA of DBA/2
(b) B10.BR male x [B10.D2 x B10]F1 female (major only)	H-2 ^{b/k}	H-2 ^d	none
(c) C3H male x [BALB/c x B6]F1 female (major + minor)	H-2 ^{b/k}	H-2 ^d	Noninherited MiHA of B6 and BALB/c
	H-2 ^{d/k}	H-2 ^b	Noninherited MiHA of B6 and BALB/c

NIMA-exposed mice could be classified into high responders (HR) and low responders (LR). The level of MMc in the LR group was significantly higher than that in the HR group, supporting the recent report in reference 17. Moreover, the NIMA tolerogenic effect was associated with Foxp3 expression and the induction of regulatory T cells in a NIMA mouse model with an H-2-mismatched and MiHA-matched combination. Our results demonstrated that there was an unevenness in the acquisition and maintenance of MMc in offspring in a breeding which excluded any role for differential inheritance of MiHA. This variability amongst offspring was not due solely to differences in MiHA gene inheritance, but seemed intrinsic to mammalian reproduction; i.e., allogeneic pregnancy and nursing itself.^{16,17}

Although several reports have described a tolerogenic NIMA effect,^{1,16,18} severe GVHD has still been experienced and methods to predict severe GVHD have not been found.¹⁹⁻²¹ To further examine the immunological mechanism underlying the tolerogenic NIMA effect in vitro, we have examined the frequency of IFN γ -producing alloreactive cells using an ELISPOT assay combining with MLR (MLR-ELISPOT).¹⁵ We detected a potent response by IFN γ -producing cells from the NIMA-exposed HR group (H-2^{d/k}, NIMA^b) and NIMA-nonexposed mice (H-2^{d/k}) to B10 stimulator cells as compared with those from NIMA-exposed LR group (H-2^{d/k}, NIMA^b) (Table 1b). Moreover, we described the predictable NIMA tolerogenic reactivity in another NIMA model with major- and minor-mismatched combination (Table 1c). These mice were affected by both major and minor NIMA just like the conventional NIMA model.^{1,18} Collectively, these results demonstrate that it is possible to

predict the immunological tolerance to NIMA in major and minor mismatched transplants.

Finally, NIMA effects directed toward MHC antigen were divided into high (immunogenic) and low (tolerogenic) reactivities. These effects were correlated with MMc and Foxp3 expression. The reactivities were predictable by MLR-ELISPOT assay. Therefore, non-T cell depleted NIMA-mismatched haploidentical transplantation could be performed more safely just by evaluating IFN γ -producing cells of donors against NIMA before transplantation.

References

- Andrassy J, Kusaka S, Jankowska-Gan E, Torrealba JR, Haynes LD, Marthaler BR, et al. Tolerance to noninherited maternal MHC antigens in mice. *J Immunol* 2003; 171:5554-61.
- Burlingham WJ, Grailer AP, Heisey DM, Claas FH, Norman D, Mohanakumar T, et al. The effect of tolerance to noninherited maternal HLA antigens on the survival of renal transplants from sibling donors. *N Engl J Med* 1998; 339:1657-64.
- Verhasselt V, Milcent V, Cazareth J, Kanda A, Fleury S, Dombrowicz D, et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. *Nat Med* 2008; 14:170-5.
- Molitor-Dart ML, Andrassy J, Haynes LD, Burlingham WJ. Tolerance induction or sensitization in mice exposed to noninherited maternal antigens (NIMA). *Am J Transplant* 2008; 8:2307-15.
- Mold JE, Michaelsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, et al. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. *Science* 2008; 322:1562-5.
- Verdijk RM, Kloosterman A, Pool J, van de Keur M, Naipal AM, van Halteren AG, et al. Pregnancy induces minor histocompatibility antigen-specific cytotoxic T cells: implications for stem cell transplantation and immunotherapy. *Blood* 2004; 103:1961-4.
- Mendoza LM, Paz P, Zuberi A, Christianson G, Roopenian D, Shastri N. Minors held by majors: the H13 minor histocompatibility locus defined as a peptide/MHC class I complex. *Immunity* 1997; 7:461-72.
- Choi EY, Yoshimura Y, Christianson GJ, Sproule TJ, Malarkannan S, Shastri N, et al. Quantitative analysis of the immune response to mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility antigen dominates over all others. *J Immunol* 2001; 166:4370-9.
- Roopenian D, Choi EY, Brown A. The immunogenomics of minor histocompatibility antigens. *Immunol Rev* 2002; 190:86-94.

- Choi EY, Christianson GJ, Yoshimura Y, Jung N, Sproule TJ, Malarkannan S, et al. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. *Blood* 2002; 100:4259-65.
- Yang J, Jaramillo A, Liu W, Olack B, Yoshimura Y, Joyce S, et al. Chronic rejection of murine cardiac allografts discordant at the H13 minor histocompatibility antigen correlates with the generation of the H13-specific CD8⁺ cytotoxic T cells. *Transplantation* 2003; 76:84-91.
- Eden PA, Christianson GJ, Fontaine P, Wettstein PJ, Perreault C, Roopenian DC. Biochemical and immunogenetic analysis of an immunodominant peptide (B6dom1) encoded by the classical H7 minor histocompatibility locus. *J Immunol* 1999; 162:4502-10.
- Malarkannan S, Horng T, Eden P, Gonzalez F, Shih P, Brouwenstijn N, et al. Differences that matter: major cytotoxic T cell-stimulating minor histocompatibility antigens. *Immunity* 2000; 13:333-44.
- Sanderson CJ, Frost P. The induction of tumour immunity in mice using glutaraldehyde-treated tumor cells. *Nature* 1974; 248:690-1.
- Araki M, Hirayama M, Azuma E, Kumamoto T, Iwamoto S, Toyoda H, et al. Prediction of reactivity to noninherited maternal antigen in MHC-mismatched, minor histocompatibility antigen-matched stem cell transplantation in a mouse model. *J Immunol* 2010; 185:7739-45.
- Aoyama K, Koyama M, Matsuoka K, Hashimoto D, Ichinohe T, Harada M, et al. Improved outcome of allogeneic bone marrow transplantation due to breastfeeding-induced tolerance to maternal antigens. *Blood* 2009; 113:1829-33.
- Dutta P, Molitor-Dart M, Bobadilla JL, Roenneburg DA, Yan Z, Torrealba JR, et al. Microchimerism is strongly correlated with tolerance to noninherited maternal antigens in mice. *Blood* 2009; 114:3578-87.
- Matsuoka K, Ichinohe T, Hashimoto D, Asakura S, Tanimoto M, Teshima T. Fetal tolerance to maternal antigens improves the outcome of allogeneic bone marrow transplantation by a CD4⁺ CD25⁺ T-cell-dependent mechanism. *Blood* 2006; 107:404-9.
- Ichinohe T, Uchiyama T, Shimazaki C, Matsuo K, Tamaki S, Hino M, et al. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. *Blood* 2004; 104:3821-8.
- Okumura H, Yamaguchi M, Kotani T, Sugimori N, Sugimori C, Ozaki J, et al. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings. *Eur J Haematol* 2007; 78:157-60.
- Kanda J, Ichinohe T, Shimazaki C, Hamaguchi M, Watanabe A, Ishida H, et al. Long-term survival after HLA-haploidentical SCT from noninherited maternal antigen-mismatched family donors: impact of chronic GVHD. *Bone Marrow Transplant* 2009; 44:327-9.